Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories : LAUNCHES THE FIRST INFANT FORMULA IN CANADA WITH AN INGREDIENT IDENTICAL IN STRUCTURE TO IMMUNE COMPONENT FOUND IN BREAST MILK

11/18/2020 | 09:44am EDT

MONTREAL - Abbott (NYSE: ABT) launched its most innovative infant formula yet, Similac Pro-Advance with 2'-Fucosyllactose Oligosaccharide(+) (2'-FL(+)), which is the first product in Canada with this breakthrough ingredient in infant formula.

Breast milk is considered the gold standard to feed an infant, and breastfed babies tend to have stronger immune systems compared to those who are fed formula. This is due in part to the many immune components found in breastmilk, including the protective qualities of human milk oligosaccharides (HMOs).1,5,6,7 HMOs are the third most abundant solid component of breast milk after fat and carbohydrates (lactose1,8), and research has shown they play a fundamental role in a baby's digestive health and immunity.1,3,9 One of the best-known functions of HMOs is that they act as prebiotics, nourishing the good bacteria in the baby's gut.1,10 2'-fucosyllactose (2'-FL) (pronounced 2 fyou-ko-sil-lac-tose) is the most abundant HMO found in the breast milk of most mothers.11,12

For some parents, breast milk is not always available or chosen. And, for babies who are not exclusively breastfed, infant formula is the only suitable and safe alternative. That's why Abbott developed a new Similac formula with 2'-FL(+), which is an ingredient identical in structure to 2'-FL HMO, an immune component found in breast milk.2,3,4 Abbott is a leader in HMO and 2'-FL(+) research, and has sponsored at least 20 clinical and pre-clinical studies on the topic, leading the company to develop Similac Pro-Advance with 2'-FL(+).

New understanding and scientific developments have allowed Abbott's scientists to harness the power of 2'-FL(+) in infant formula, an innovation designed to help support a baby's developing immune system. New data continues to deepen the evidence for the beneficial impact of 2'-FL on infant gut and immune development.

'Parents want to know that their child is getting the nutrition they need, and breastfeeding is known to have many health benefits,' says Nishta Saxena, a Registered Dietician and Nutritionist of her own practice, Vibrant Nutrition. 'Parents who use formula can feel more confident, knowing that the inclusion of 2'-FL(+) in infant formula was inspired by an immune component found in human milk.'

Rachael Buck, Ph.D., Research Fellow at Abbott said, 'At Abbott, we know that breast milk provides protective components a baby needs to thrive. That's why we have spent more than 20 years researching HMOs and their impact on immune and gut health so that we can understand the role they play in supporting the development of a baby's immune system during the critical first years of their life. We wanted to replicate 2'-FL found in breast milk so that more babies could possibly benefit.'

Research published in the Journal of Nutrition studied more than 200 babies to compare the differences between breastfed babies and those fed formula with or without 2'-FL(+).2,4 The peer-reviewed study found that formula-fed babies had five gaps in immune markers compared to the breastfed group. When babies were fed formula with 2'-FL(+), these measures of immune function were more like those seen in the breastfed reference group.2 This shows that 2'-FL(+) may help support baby's developing immune system.

Similac Pro-Advance with 2'-FL(+) will be available in all major retailers.

Important notice: Breast milk is best for babies, as it contains many immune factors not available in infant formula and its use is recommended for as long as possible during infancy.

Breastfeeding provides many benefits to both mother and baby. We recommend that you speak to your healthcare professional for advice on how to feed your baby.

(+)Not derived from human milk; identical structure to 2'-FL found in breast milk.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Contact:

Brandi Martin

Tel: +1 614-208-1852

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ABBOTT LABORATORIES
09/23ABBOTT : Hosts Conference Call for Third-Quarter Earnings
PR
09/20GLOBAL MARKETS LIVE : Universal Music Group, China Evergrande, ENI, Prudential, Microsoft...
09/20ABBOTT LABORATORIES : Gets FDA Clearance for Portico with FlexNav Transcatheter Aortic Val..
MT
09/20Abbott Receives FDA Approval for Minimally Invasive Portico with FlexNav TAVR System to..
CI
09/15ABBOTT LABORATORIES : to Pay Quarterly Cash Dividend of $0.45 a Share on Nov. 15 to Shareh..
MT
09/15ABBOTT : Declares 391st Consecutive Quarterly Dividend
PR
09/15Abbott Laboratories Declares Quarterly Dividend, Payable on November 15, 2021
CI
09/13GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
09/13INSIDER SELL : Abbott Laboratories
MT
09/10QIAGEN N : 3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate
RE
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2021 39 807 M - -
Net income 2021 5 837 M - -
Net Debt 2021 8 454 M - -
P/E ratio 2021 37,7x
Yield 2021 1,37%
Capitalization 220 B 220 B -
EV / Sales 2021 5,75x
EV / Sales 2022 5,73x
Nbr of Employees 109 000
Free-Float 88,8%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 124,37 $
Average target price 130,04 $
Spread / Average Target 4,56%
EPS Revisions
Managers and Directors
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES13.59%220 485
MEDTRONIC PLC11.00%174 982
BECTON, DICKINSON AND COMPANY1.18%72 711
HOYA CORPORATION30.69%62 143
ALIGN TECHNOLOGY, INC.35.72%57 302
SARTORIUS STEDIM BIOTECH77.82%55 891